What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Alliance for Clinical Trials in Oncology

Home
United States
Boston, MA
Alliance for Clinical Trials in Oncology

Alliance develops and conducts cancer clinical trials as part of NCI National Clinical Trials Network

03/30/2026

🚨 Now Enrolling: A021901 / B LuRE Clinical Trial 🚨
Led by Thomas Hope, MD of UCSF and Suki Padda, MD of Fox Chase Cancer Center, this trial is evaluating a new treatment for patients with bronchial neuroendocrine tumors.
🔬 B LuRE is comparing a radioactive drug (a form of targeted radiopharmaceutical therapy) with standard chemotherapy to see which option offers better outcomes for people living with bronchial neuroendocrine tumors.
👉 Learn more at https://bit.ly/Alliance-A021901

03/27/2026

🚨 Now Enrolling! Phase III ShortStop HER2 Study (A012303) 🚨
Led by Adrienne Waks, MD, of the Dana Farber Cancer Institute, A012303 (ShortStop HER2), is Phase III clinical trial now enrolling.
👉 This study asks if people with early stage HER2 positive breast cancer who have no cancer left after neoadjuvant chemotherapy + HER2 targeted therapy, can safely have less treatment after surgery?
🔬 Learn more or share the trial information here:
👉 https://bit.ly/Alliance-A012303

03/26/2026

🔍 New publication alert!
Data from Alliance A032201 has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Published in Clinical and Translational Science by lead authors Michael Morris, MD, of Memorial Sloan Kettering Cancer Center and Nadine Norris, PhD, of the Mayo Clinic, this analysis of could lead to more personalized treatments for patients.
🔗 Learn more: https://bit.ly/Alliance-A012301

03/25/2026

Landmark Alliance ATOMIC trial establishes new standard of care for patients with dMMR . Learn more, visit https://bit.ly/ATOMIC2026 -A021502

03/25/2026

📢 New Clinical Trial Alert! Jennifer Ligibel, MD (Dana-Farber Cancer Institute) and Kathryn Schmitz, PhD (UPMC Hillman Cancer Center) are leading Alliance A222302, a study exploring the feasibility of a telehealth exercise program for cancer patients. The goal? To help reduce fatigue and disability and improve quality of life. Learn more about the trial here: https://bit.ly/DEFEND-trial

03/24/2026

Missed Alliance’s Best of ASH and SABCS webinar? It’s now available online. Learn from investigators about new advances impacting treatments for breast , multiple myeloma and . https://bit.ly/AllianceWebinar2026

03/24/2026

Trial Tuesday: Advancing Care for Bladder Cancer
Dr. Matt Galsky of Icahn Mouth Sinai leads the Alliance A032103 (MODERN) trial, investigating whether DNA released from tumor cells into the blood can help identify the best immunotherapy treatment after surgery for bladder cancer.
📌 Learn more: https://bit.ly/Alliance-A032103

03/23/2026

💜 March is Multiple Myeloma Awareness Month
This month, the Alliance for Clinical Trials in Oncology is shining a light on new research designed to help people living with multiple myeloma — a rare blood cancer that affects plasma cells. Thanks to ongoing scientific progress, survival rates continue to improve.
🧬 One of the Alliance’s highlighted studies is A062101, Phase I/II trial. This trial brings together:
✨ Iberdomide — a therapy that may activate the immune system to help fight cancer cells
✨ Belantamab mafodotin — designed to attach directly to the BCMA protein on myeloma cells
✨ Dexamethasone — often used to help ease side effects and support treatment
Together, these medicines aim to target cancer cells more effectively — giving patients another path forward when other options haven’t worked.
https://bit.ly/Myeloma2026

03/23/2026

Now enrolling! The Alliance A032103 (GAIN) trial is a phase III study evaluating whether adding gemcitabine, a well-established chemotherapeutic agent, to BCG can reduce high-grade recurrence rates in patients with non-muscle invasive bladder cancer who have experienced recurrence after BCG.
📌 Learn more at https://bit.ly/Alliance-GAIN-BCG

03/20/2026

🚨 Sascha Tuchman, MD, of UNC Lineberger leads Alliance A062102, a new study for people with multiple myeloma. This trial is looking at if a daily pill called iberdomide can help keep myeloma under control longer compared with the usual approach of simply monitoring the disease after initial treatment.
➡️ Learn more about the study: https://bit.ly/Alliance-A062102

03/19/2026

At the Society of Surgical Oncology’s annual meeting, Eric Miller, MD, PhD, of Ohio State and Sepideh Gholami, MD, of Northwell Health presented new insights from A022101 / NRG GI009 (ERAsur), a pivotal clinical trial exploring whether adding radiation therapy to chemotherapy can improve outcomes for patients with locally advanced colorectal cancer.
🔬This study represents a major collaborative effort between NRG Oncology and the Alliance for Clinical Trials in Oncology, leading cooperative cancer organizations. As we continue to push for more effective, personalized treatment strategies, trials like ERAsur are essential for shaping the future of colorectal cancer care.
✨ With March marking , it’s inspiring to see such meaningful progress and dedication from leaders in surgical oncology, radiation oncology, and medical oncology working together to improve patient outcomes. 🙌
Learn more about the presentation and study details here: https://ow.ly/KQGH50Ywvqw

03/19/2026

Rana McKay, MD, of UCSD Health leads Alliance A031801 (RadiCaL) exploring if adding radium-223 dichloride to the standard cabozantinib can improve outcomes.
What are these treatments?
• Cabozantinib is a pill that helps slow cancer growth by blocking signals tumors use to spread.
• Radium-223 dichloride is a targeted radioactive medicine that goes to areas in the bone where cancer has spread, helping destroy cancer cells and reduce bone pain.
Learn more: http://bit.ly/AllianceA031801

Address

Alliance For Clinical Trials In Oncology, Office Of The Group Chair 221 Longwood Avenue, Room 108
Boston, MA
02115

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Telephone

+16177328919

Website

http://www.AllianceforClinicalTrialsinOncology.org/

Alerts

Be the first to know and let us send you an email when Alliance for Clinical Trials in Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.